National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Fidaxomicin (Dificlir®)

Fidaxomicin is indicated for the treatment of CDI also known as CDAD in adult patients.

Rapid Review

Commenced Completed Outcome
09/03/2012 23/03/2012 Full Pharmacoeconomic Evaluation Recommended.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
05/12/2012 05/02/2013 Reimbursement recommended

Fidaxomicin (Dificlir®) may be considered a cost-effective use of resources. It should be prescribed according to the recommendations outlined in the recently updated National Clostridium difficile Guidelines (due to be completed in February 2013

Fidaxomicin (Dificlir)